Cell Cycle Regulation: Key Roles of CDKs and Cyclins

Cancer originates from mutations in genes that regulate cell division. Proto-oncogenes normally promote cell cycle progression; when mutated, they become oncogenes that continuously stimulate division (like a stuck gas pedal). Tumor suppressor genes normally inhibit cell cycle and promote apoptosis; when mutated, they fail to stop abnormal cells (like failed brakes). Both gene categories must fail for cancer to develop. The Ras gene family exemplifies proto-oncogenes, while BRCA genes and p53 are key tumor suppressors.

Cancer arises from mutations disrupting normal cell cycle regulation. Proto-oncogenes normally promote controlled growth; when mutated by carcinogens (UV radiation, chemicals, pollution), they become oncogenes causing uncontrolled proliferation. Tumor suppressor genes normally inhibit excessive growth; their loss enables unchecked division. The ras oncogene (30% of cancers) causes constitutive activation independent of external signals. The p53 tumor suppressor (50% of cancers) normally halts damaged cells at the G1 checkpoint, allowing repair or triggering apoptosis; mutated p53 fails to stop damaged cells from replicating, leading to tumor formation.

RAS genes (K-RAS, H-RAS, N-RAS) are the most common proto-oncogene abnormalities, found in 15-20% of tumors. K-RAS mutations occur in colon, lung, and pancreatic tumors; H-RAS in bladder and kidney tumors; N-RAS in melanomas. RAS activation involves GTP binding (active) and GTP hydrolysis (inactive), with mutations blocking hydrolysis causing constitutive activation. Additional oncogenes include ABL (CML through BCR-ABL fusion), BRAF (melanomas, benign nevi), and JAK2. Chromosomal translocations create fusion genes: ABL translocates from chromosome 9 to 22 in CML; MYC translocates from chromosome 8 to 14 in Burkitt's lymphoma; MYC amplification (double minutes) causes overexpression in small cell carcinomas and neuroblastoma. Cell cycle progression requires cyclin-CDK complexes that phosphorylate RB. Cyclin D binds CDK4/6 for G1 to S transition; Cyclin E binds CDK2 for G1 to S; Cyclin A binds CDK2/1 for G1 to S to G2; Cyclin B binds CDK1 for G2 to M. CDK inhibitors include p16 (binds cyclin D-CDK4, promotes RB inhibition), p21 (induced by p53 in response to DNA damage), p27 (stimulated by TGF-beta), and p14 ARF (inhibits MDM2, increasing p53 levels). Checkpoint components include RB (stops proliferation when activated), p53 (responds to DNA damage, oncogenic stress, or hypoxia), and p21 (inhibits CDKs).

Proto-oncogenes are normal genes encoding proteins that stimulate cell division (growth factors, signal transducers, transcription factors). Oncogenes are mutated proto-oncogenes that cause hyperstimulation of the cell cycle, leading to excessive proliferation and cancer. Unlike tumor suppressor genes where loss of function causes cancer, oncogenes cause cancer through gain of function. Key oncogenes include HER2 and HER3 (breast cancer) and RAS genes (various cancers). The presence of oncogenes, rather than their absence, is associated with cancer development.

Oncogene activation leads to persistent cell proliferation signaling. RAS proteins cycle between active GTP-bound and inactive GDP-bound states; oncogenic mutations prevent GTP hydrolysis, locking RAS in the active state. EGFR mutations cause constitutive activation, while KRAS mutations are found in 90% of pancreatic cancers. MYC is a transcription factor that promotes cell proliferation by activating genes involved in cell cycle progression.

p53 is known as the guardian of the cell cycle and acts as a tumor suppressor gene. When checkpoints detect problems such as DNA damage, they recruit p53 which then activates p21 cyclin inhibitor. This inhibits cyclin-dependent kinases, halting cell cycle progression. If DNA repair fails, p53 triggers apoptosis (programmed cell death) to eliminate damaged cells.

The G1/S transition checkpoint, also called the restriction point, evaluates whether conditions are optimal for cell division by assessing growth factors and internal DNA integrity. DNA damage sensors ATM and ATR detect lesions, triggering Chk2 and Chk1 kinases that phosphorylate p53. Stabilized p53 activates p21, inhibiting cyclin-CDK complexes (cyclin D-CDK4 and cyclin E-CDK2) to pause the cell cycle. If repair fails, p53 initiates apoptosis to prevent mutation accumulation and tumorigenesis.

Cell cycle checkpoints are control points where the cell assesses whether conditions are favorable for progression. If problems are detected at checkpoints, the cell can either repair the damage and continue, or if the damage is irreparable, the cell undergoes apoptosis (programmed cell death). This prevents damaged cells from dividing and potentially becoming cancerous. Apoptosis is a controlled, beneficial process that eliminates cells with damaged DNA, while necrosis is unprogrammed cell death resulting from injury, which is harmful to the organism.

When DNA damage is too severe to be repaired, p53 can trigger apoptosis (programmed cell death) instead of cell cycle arrest. This prevents cells with irreparable DNA damage from dividing and potentially developing into cancer. The decision between cell cycle arrest and apoptosis depends on the severity of DNA damage and the cell's ability to repair it.

Apoptosis, or programmed cell death, is essential for development, tissue homeostasis, and defense against pathogens. Two main pathways exist: extrinsic (death receptor pathway) initiated by external ligands binding to cell surface receptors, and intrinsic (mitochondrial pathway) triggered by internal cellular stress. Both converge on caspase activation, particularly caspase 3, which executes cellular dismantling. The p53 protein acts as the 'guardian of the genome,' regulating the growth-death balance. Under normal conditions, MDM2 keeps p53 levels low through ubiquitin-mediated degradation. When DNA damage occurs, checkpoint proteins like ATM phosphorylate both p53 and MDM2—inactivating MDM2 while activating p53. Activated p53 induces p21 to halt cell cycle progression via cyclin-CDK inhibition, providing time for DNA repair, or triggers apoptosis by promoting Bax-mediated mitochondrial pore formation and cytochrome c release. Mutations disrupting this regulatory network lead to uncontrolled cell proliferation and cancer development.

CDK4/6 inhibitors (palbociclib, ribociclib) block cyclin D-CDK4/6-Rb-E2F pathway, preventing cell cycle progression. They are added to aromatase inhibitors for metastatic ER/PR positive breast cancer to enhance treatment efficacy.

CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) directly inhibit cyclin-dependent kinases 4 and 6. This prevents phosphorylation of RB protein, preventing E2F release and cell cycle progression. These drugs are used in hormone receptor-positive breast cancer, often in combination with endocrine therapy.

Breast cancer treatment requires both local (surgery, radiation) and systemic approaches. While local treatments remove visible tumors, systemic therapy is essential because cancer cells can spread through blood to distant organs. The three main systemic treatments are hormone therapy, targeted therapy, and chemotherapy. For estrogen receptor-positive breast cancer (60-70% of cases), hormone therapy blocks estrogen's role in cancer cell survival. CDK4/6 inhibitors represent a new class of targeted therapy that inhibits cyclin-dependent kinases 4 and 6, enzymes that activate cell cycle progression. Three FDA-approved CDK4/6 inhibitors are palbociclib, ribociclib, and abemaciclib. Abemaciclib shows potent CDK4 inhibition at low doses and inhibits multiple cell cycle checkpoints. The MONARCH 2 trial evaluated abemaciclib in high-risk hormone receptor-positive breast cancer patients with at least one high-risk feature: lymph node involvement (N2 disease), high histological grade (grade 3), high Ki-67 expression, or tumor size ≥5cm. Results showed abemaciclib significantly reduced recurrence risk: at 2 years, risk decreased by 3.5%; by 3 years, risk reduction reached 30% (absolute difference of 5%), exceeding the trial's primary endpoint. In high-risk subgroups (high Ki-67), risk reduction was 37%. Abemaciclib received FDA approval in March 2020 and Korean approval in November 2021. The drug is indicated for high-risk hormone receptor-positive breast cancer patients who have completed standard treatment. Abemaciclib's efficacy was confirmed in long-term follow-up. At 4 years, recurrence risk reduction increased to 33%, with metastatic progression reduction reaching 34%. For metastatic breast cancer, abemaciclib reduced metastatic progression by approximately 34% over 4 years. The drug has two main side effects: diarrhea and neutropenia. Diarrhea typically occurs within the first 1-2 weeks and is often severe (grade 3+). Management includes antidiarrheal medications and temporary dose interruption. Interestingly, interrupting treatment for 1-2 weeks and resuming often prevents diarrhea recurrence. Neutropenia may require growth factor support. Treatment is taken continuously for 2 years, with monitoring every 2-4 weeks initially. When combined with hormone therapy, abemaciclib may reduce some hormone therapy side effects like joint pain and hot flashes.

CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) represent a new class of targeted therapies for metastatic breast cancer. These drugs work by inhibiting cyclin-dependent kinases 4 and 6, which regulate cell cycle progression, thereby preventing cancer cells from dividing and growing. These drugs have shown significant efficacy in slowing disease progression in metastatic breast cancer and are now being used as first-line treatment options for hormone receptor-positive metastatic disease. Abemaciclib demonstrated promising results in clinical trials at the 2019 San Antonio Breast Cancer Symposium, showing improved survival rates when used in combination with hormonal therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. These results led to regulatory approval discussions and represent a significant advancement in treatment options for this patient population.

CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are FDA-approved medications that block cyclin-dependent kinases 4 and 6 to slow cancer cell proliferation; in early-stage hormone receptor-positive/HER2-negative breast cancer, abemaciclib (Verzenio) received FDA approval in 2024 for high-risk patients based on the MonarchE trial showing significant disease-free survival improvement when combined with endocrine therapy, while ribociclib (Kisqali) showed similar benefits in the NATALEE trial with a slightly lower dose of 400mg daily; these treatments are typically given for 2-3 years alongside 5+ years of endocrine therapy and are well-tolerated despite common side effects like neutropenia and diarrhea.